[go: up one dir, main page]

CL2019000431A1 - Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814) - Google Patents

Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)

Info

Publication number
CL2019000431A1
CL2019000431A1 CL2019000431A CL2019000431A CL2019000431A1 CL 2019000431 A1 CL2019000431 A1 CL 2019000431A1 CL 2019000431 A CL2019000431 A CL 2019000431A CL 2019000431 A CL2019000431 A CL 2019000431A CL 2019000431 A1 CL2019000431 A1 CL 2019000431A1
Authority
CL
Chile
Prior art keywords
tetrahydro
indoles
pyrido
estrogen receptor
divisional application
Prior art date
Application number
CL2019000431A
Other languages
English (en)
Inventor
Sharada Labadie
Xiaojing Wang
Nicholas Charles Ray
Jun Liang
Jason Zbieg
Birong Zhang
Daniel Fred Ortwine
Simon Charles Goodacre
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2019000431A1 publication Critical patent/CL2019000431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN COMPUESTOS TETRAHIDRO-PIRIDO[3,4-B]INDOL-1-ILO MODULADORES DE LOS RECEPTORES DE ESTRÓGENOS, QUE TIENEN LA ESTRUCTURA DE FÓRMULA I: I, SUS ESTEREOISÓMEROS, TAUTÓMEROS O SALES FARMACÉUTICAMENTE ACEPTABLES, CON LOS SUSTITUYENTES Y CARACTERÍSTICAS ESTRUCTURALES DESCRITAS. COMPOSICIONES FARMACÉUTICAS Y MEDICAMENTOS QUE LOS COMPRENDEN, Y SUS USOS, SOLOS O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA TRATAR ENFERMEDADES MEDIADAS O QUE DEPENDEN DE RECEPTORES DE ESTRÓGENOS.
CL2019000431A 2014-12-18 2019-02-18 Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814) CL2019000431A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093929P 2014-12-18 2014-12-18
US201562110998P 2015-02-02 2015-02-02
US201562142077P 2015-04-02 2015-04-02

Publications (1)

Publication Number Publication Date
CL2019000431A1 true CL2019000431A1 (es) 2019-07-12

Family

ID=54850193

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017000814A CL2017000814A1 (es) 2014-12-18 2017-04-04 Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos.
CL2019000431A CL2019000431A1 (es) 2014-12-18 2019-02-18 Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017000814A CL2017000814A1 (es) 2014-12-18 2017-04-04 Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos.

Country Status (33)

Country Link
US (4) US9980947B2 (es)
EP (2) EP3760623A1 (es)
JP (3) JP6679147B2 (es)
KR (4) KR102785474B1 (es)
CN (6) CN107108611B (es)
AU (3) AU2015367509B2 (es)
BR (1) BR112017007662B1 (es)
CA (1) CA2963736A1 (es)
CL (2) CL2017000814A1 (es)
CO (1) CO2017003070A2 (es)
CR (1) CR20170250A (es)
DK (1) DK3233852T3 (es)
EA (1) EA032311B1 (es)
ES (1) ES2819448T3 (es)
HR (1) HRP20201396T1 (es)
HU (1) HUE050466T2 (es)
IL (5) IL287326B2 (es)
LT (1) LT3233852T (es)
MA (1) MA53837A (es)
MX (3) MX376763B (es)
MY (1) MY198354A (es)
NZ (1) NZ769496A (es)
PE (1) PE20171330A1 (es)
PH (1) PH12017501140A1 (es)
PL (1) PL3233852T3 (es)
PT (1) PT3233852T (es)
RS (1) RS60824B1 (es)
SG (3) SG10201913913VA (es)
SI (1) SI3233852T1 (es)
TW (5) TWI874834B (es)
UA (1) UA122868C2 (es)
WO (1) WO2016097072A1 (es)
ZA (1) ZA202108745B (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250004174A (ko) 2014-06-27 2025-01-07 노그라 파마 리미티드 아릴 수용체 조정제, 및 그의 제조 및 사용 방법
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
CN107108611B (zh) 2014-12-18 2020-09-25 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
WO2017100715A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
JP6905539B2 (ja) * 2016-02-05 2021-07-21 インベンティスバイオ リミテッド ライアビリティ カンパニー 選択的エストロゲン受容体分解剤およびその使用
HRP20211043T1 (hr) 2016-02-15 2021-10-01 Sanofi Derivati 6,7-dihidro-5h-benzo[7]anulena kao modulatori estrogenskih receptora
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
JP2019521983A (ja) * 2016-06-16 2019-08-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用
CN107543871A (zh) * 2016-06-29 2018-01-05 重庆华邦胜凯制药有限公司 分离测定帕布昔利布中间体z1及其有关物质的方法
WO2018005860A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
TW201815789A (zh) 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
AU2017336564A1 (en) * 2016-09-27 2019-03-14 Radius Pharmaceuticals, Inc. Methods for treating ovarian cancer
TWI735681B (zh) 2016-10-24 2021-08-11 瑞典商阿斯特捷利康公司 化合物
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
US10774081B2 (en) * 2016-10-28 2020-09-15 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Indolo substituted piperidine compound as estrogen receptor down-regulator
EP3541809B1 (en) * 2016-11-17 2025-06-25 Sanofi Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
EA037533B9 (ru) * 2016-12-16 2021-05-27 Астразенека Аб 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
CA3048057A1 (en) 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
WO2018130123A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
PL3494116T3 (pl) * 2017-01-30 2020-04-30 Astrazeneca Ab Modulatory receptora estrogenowego
CA3052810A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
MX392531B (es) 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CA3082276C (en) * 2017-11-14 2022-08-16 Anlin Pharmaceuticals, Llc Heterocyclic compounds and their application in medicine
EA038160B1 (ru) * 2017-11-30 2021-07-15 Астразенека Аб Модуляторы рецептора эстрогена
US10519152B2 (en) 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
SG11202006942WA (en) 2018-01-22 2020-08-28 Radius Pharmaceuticals Inc Estrogen receptor-modulating compounds
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
MX2020012066A (es) 2018-05-14 2021-04-28 Nuvation Bio Inc Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
AU2019290545B2 (en) * 2018-06-21 2022-04-14 F. Hoffmann-La Roche Ag Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
CA3109090A1 (en) * 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
CN112638869B (zh) 2018-09-07 2025-04-25 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
KR20210131316A (ko) * 2019-02-27 2021-11-02 밀레니엄 파머슈티컬스 인코퍼레이티드 Sumo-활성화 효소 저해제 및 관문 저해제의 투여
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
ES2969383T3 (es) * 2019-06-17 2024-05-17 Ucb Pharma Gmbh Derivados de N-(fenil)-indol-3-sulfonamida y compuestos relacionados como moduladores de GPR17 para el tratamiento de trastornos del SNC tales como la esclerosis múltiple
KR20220034129A (ko) * 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
CN114174297B (zh) 2019-07-22 2024-07-12 雷迪厄斯制药公司 雌激素受体调节化合物
AU2020326691A1 (en) 2019-08-06 2022-03-03 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
US20220370625A1 (en) * 2019-09-19 2022-11-24 Totus Medicines Inc. Therapeutic conjugates
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
NZ790033A (en) * 2019-12-20 2025-09-26 Recurium Ip Holdings Llc Combinations
CN114901277B (zh) 2019-12-20 2024-05-17 C4医药公司 用于egfr降解的异吲哚啉酮和吲唑化合物
WO2021143822A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 并环酰亚胺类衍生物、其制备方法及其在医药上的应用
WO2021143816A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
MX2022010952A (es) 2020-03-05 2022-10-07 C4 Therapeutics Inc Compuestos para la degradacion dirigida de brd9.
CA3169679A1 (en) 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
CN115667275B (zh) * 2020-04-21 2024-02-23 南京再明医药有限公司 含硼化合物及其应用
PH12022552755A1 (en) 2020-04-24 2024-03-25 Astrazeneca Ab Pharmaceutical formulations
MX2022013391A (es) 2020-04-24 2022-11-30 Astrazeneca Ab Pauta posologica para el tratamiento del cancer.
WO2021231250A1 (en) * 2020-05-12 2021-11-18 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
CA3178707A1 (en) * 2020-05-15 2021-11-18 Peng GU Pyrrolidine compound and use thereof
WO2021249533A1 (zh) * 2020-06-12 2021-12-16 江苏先声药业有限公司 雌激素受体调节剂化合物及其用途
BR112022026981A2 (pt) * 2020-06-30 2023-01-24 Genentech Inc Processos para a preparação de um composto e processo para a síntese de um composto
WO2022032026A1 (en) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Compounds for targeted degradation of ret
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 雌激素受体调节剂化合物及其用途
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
WO2022166983A1 (zh) * 2021-02-08 2022-08-11 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
WO2023284837A1 (zh) * 2021-07-15 2023-01-19 四川海思科制药有限公司 芳氨基衍生物雌激素受体调节剂及其用途
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
CA3233526A1 (en) * 2021-10-08 2023-04-13 Matthew Davidson Derivatives of aryl hydrocarbon receptor agonists
CN118119620A (zh) * 2021-11-12 2024-05-31 南京再明医药有限公司 用于治疗肿瘤的药物组合及其应用
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
JP2024546191A (ja) * 2021-12-28 2024-12-17 深▲セン▼揚歴医薬技術有限公司 テトラヒドロシクロヘプタインダゾール化合物の塩形、結晶
CN116804008A (zh) * 2022-03-24 2023-09-26 烟台创和生物科技有限公司 雌激素受体降解剂及其制备方法和应用
IL316096A (en) 2022-04-28 2024-12-01 Hoffmann La Roche Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3 ,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024017131A1 (zh) * 2022-07-21 2024-01-25 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
CN115109058B (zh) * 2022-07-27 2023-04-07 黑龙江中医药大学 一种用于治疗胃癌的药物及其制备方法
CN119998285A (zh) 2022-08-03 2025-05-13 百时美施贵宝公司 用于调控ret蛋白的化合物
CA3261772A1 (en) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen Receptor Modulators and Their Uses
EP4573092A1 (en) * 2022-08-19 2025-06-25 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
EP4577542A1 (en) * 2022-08-25 2025-07-02 Sanofi Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
KR20250089532A (ko) 2022-10-17 2025-06-18 아스트라제네카 아베 암 치료를 위한 serd의 조합
TW202425966A (zh) * 2022-10-28 2024-07-01 大陸商南京再明醫藥有限公司 用於治療腫瘤的藥物組合、藥物組成物及其用途
CN120530116A (zh) 2022-11-04 2025-08-22 百时美施贵宝公司 Ret-ldd蛋白抑制剂
CN120569388A (zh) 2022-11-04 2025-08-29 百时美施贵宝公司 Ret-ldd蛋白降解剂
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
CN115894485B (zh) * 2023-03-03 2023-06-27 山东绿叶制药有限公司 杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
US11773092B1 (en) 2023-03-27 2023-10-03 King Faisal University Pyrido[3,4-b]indol-1-one compounds as antibacterial agents
CN121079090A (zh) 2023-05-11 2025-12-05 阿斯利康(瑞典)有限公司 用于治疗癌症的parp1抑制剂和选择性雌激素降解剂的组合
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2025103409A1 (zh) * 2023-11-16 2025-05-22 南京同诺康医药科技有限公司 Nmt抑制剂及其制备方法和用途
CN118791392A (zh) * 2024-06-18 2024-10-18 华中科技大学 一种合成依拉司群的方法及中间体化合物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE398789C (de) 1923-03-03 1924-07-15 L V Kramolin Verfahren und Einrichtung zur Verhinderung des Mithoerens beim Telephon- und Telegraphenverkehr mittels elektrischer Wellen und zum Vielfachverkehr mittels elektromagnetischer Wellen
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
SE455604B (sv) 1982-06-29 1988-07-25 Stiftelsen Ind Organisk Elektr Sett att framstella fenetylaminer medelst elektrokemisk reduktion
US5206377A (en) 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
ES2241902T3 (es) 2000-12-08 2005-11-01 Smithkline Beecham Corporation Compuestos antibacterianos.
US7022856B2 (en) 2001-02-12 2006-04-04 Lilly Icos Llc. Carboline derivatives
US6951961B2 (en) 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
EP1670314A4 (en) 2003-09-05 2009-02-25 Sequella Inc METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
ES2401335T3 (es) * 2004-03-15 2013-04-18 Ptc Therapeutics, Inc. Derivados de carbolina útiles en la inhibición de la angiogénesis
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
JP2008508356A (ja) 2004-08-02 2008-03-21 スミスクライン ビーチャム コーポレーション Ｈｐｖ感染に有用な化合物
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
CA3052368A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2008127714A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
SI2285808T1 (sl) 2008-04-29 2014-03-31 Novartis Ag Spiro-indolni derivati za zdravljenje parazitskih bolezni
US9292307B2 (en) 2008-07-30 2016-03-22 Kyocera Corporation User interface generation apparatus
EP2323651A2 (en) 2008-08-05 2011-05-25 Summit Corporation Plc Compounds for the treatment of flaviviral infections
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
EP2414044A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Substituted indolo-piperidine compounds
US20120157401A1 (en) 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
CN102480957A (zh) * 2009-05-27 2012-05-30 Ptc医疗公司 治疗癌症及非肿瘤病症的方法
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
US20130171103A1 (en) 2010-05-27 2013-07-04 Ptc Therapeutics, Inc. Methods for treating viral conditions
JP2013528223A (ja) 2010-06-10 2013-07-08 アラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその用途
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
KR20140099556A (ko) 2010-12-16 2014-08-12 에프. 호프만-라 로슈 아게 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
EP2655367B1 (en) 2010-12-24 2016-07-06 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
US9193714B2 (en) * 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
RU2662815C2 (ru) 2012-03-23 2018-07-31 Новартис Аг Химический способ получения спироиндолонов и их промежуточных соединений
WO2013142770A1 (en) 2012-03-23 2013-09-26 Codexis, Inc. Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
DE102012209622A1 (de) 2012-06-08 2013-12-12 Robert Bosch Gmbh Zahnradmaschine mit hydrodynamisch und hydrostatisch gelagertem Lagerzapfen
EP2682119A1 (en) 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatic N-heterocycle derivatives for use as medicine
EP2738173A1 (en) 2012-11-28 2014-06-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Heterocyclic compounds as inhibitors of the sodium iodide symporter
LT3004090T (lt) 2013-05-28 2018-01-10 Astrazeneca Ab Cheminiai junginiai
JP6576916B2 (ja) 2013-06-19 2019-09-18 セラゴン ファーマシューティカルズ， インク． エストロゲン受容体モジュレーター及びその使用
CN105451735B (zh) 2013-06-19 2019-01-11 西拉根制药公司 氮杂环丁烷雌激素受体调节剂和其用途
AU2014342520B2 (en) 2013-10-28 2019-08-08 Drexel University Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
CN105916501A (zh) 2013-12-06 2016-08-31 豪夫迈·罗氏有限公司 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
CA2941161A1 (en) 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
KR20250004174A (ko) 2014-06-27 2025-01-07 노그라 파마 리미티드 아릴 수용체 조정제, 및 그의 제조 및 사용 방법
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
CN107108611B (zh) 2014-12-18 2020-09-25 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
JP6905539B2 (ja) 2016-02-05 2021-07-21 インベンティスバイオ リミテッド ライアビリティ カンパニー 選択的エストロゲン受容体分解剤およびその使用

Also Published As

Publication number Publication date
IL301960A (en) 2023-06-01
US20230045776A9 (en) 2023-02-09
EP3760623A1 (en) 2021-01-06
CN118005631A (zh) 2024-05-10
CN112375077A (zh) 2021-02-19
TWI874834B (zh) 2025-03-01
US20210236473A1 (en) 2021-08-05
JP2024028785A (ja) 2024-03-05
AU2015367509A1 (en) 2017-04-13
CN112457310A (zh) 2021-03-09
KR20250044940A (ko) 2025-04-01
MX2022007975A (es) 2022-07-05
JP7446348B2 (ja) 2024-03-08
AU2021200352A1 (en) 2021-03-18
EA201791239A8 (ru) 2019-01-31
AU2015367509B2 (en) 2020-01-02
CR20170250A (es) 2017-07-19
CL2017000814A1 (es) 2017-12-29
MX2020003532A (es) 2020-07-29
EP3233852B1 (en) 2020-07-15
US20180235945A1 (en) 2018-08-23
AU2021200352B2 (en) 2022-12-15
US20250114338A1 (en) 2025-04-10
CA2963736A1 (en) 2016-06-23
HK1243074A1 (zh) 2018-07-06
TW202534076A (zh) 2025-09-01
ES2819448T3 (es) 2021-04-16
IL287326B1 (en) 2023-05-01
PH12017501140A1 (en) 2018-03-05
IL270653B (en) 2021-12-01
IL301960B1 (en) 2024-04-01
BR112017007662A2 (pt) 2017-12-19
SI3233852T1 (sl) 2020-10-30
US9980947B2 (en) 2018-05-29
TWI875674B (zh) 2025-03-01
US20160175289A1 (en) 2016-06-23
MX395013B (es) 2025-03-24
NZ769496A (en) 2023-09-29
EP3233852A1 (en) 2017-10-25
DK3233852T3 (da) 2020-09-14
TWI784255B (zh) 2022-11-21
IL311006A (en) 2024-04-01
JP2022088416A (ja) 2022-06-14
BR112017007662B1 (pt) 2021-11-03
RS60824B1 (sr) 2020-10-30
LT3233852T (lt) 2020-10-12
TW202506643A (zh) 2025-02-16
UA122868C2 (uk) 2021-01-13
JP7128169B2 (ja) 2022-08-30
CN112375078A (zh) 2021-02-19
HRP20201396T1 (hr) 2020-11-27
SG11201704401TA (en) 2017-07-28
BR112017007662A8 (pt) 2021-10-05
ZA202108745B (en) 2024-10-30
MX376763B (es) 2025-03-07
CN107108611A (zh) 2017-08-29
SG10201913913VA (en) 2020-03-30
KR102559719B1 (ko) 2023-07-26
HUE050466T2 (hu) 2020-12-28
EA032311B1 (ru) 2019-05-31
CN117865872A (zh) 2024-04-12
AU2020200407A1 (en) 2020-02-13
NZ730448A (en) 2021-02-26
KR20230113416A (ko) 2023-07-28
CN112375078B (zh) 2023-12-19
TW201636348A (zh) 2016-10-16
JP2020073493A (ja) 2020-05-14
IL287326A (en) 2021-12-01
KR20250044939A (ko) 2025-04-01
MX2017007489A (es) 2017-10-18
MA53837A (fr) 2021-11-10
JP6679147B2 (ja) 2020-04-15
IL301960B2 (en) 2024-08-01
KR102785474B1 (ko) 2025-03-26
PE20171330A1 (es) 2017-09-13
IL287326B2 (en) 2023-09-01
TWI699363B (zh) 2020-07-21
TW202323253A (zh) 2023-06-16
WO2016097072A1 (en) 2016-06-23
EA201791239A1 (ru) 2017-10-31
PT3233852T (pt) 2020-09-10
KR20170097651A (ko) 2017-08-28
CN107108611B (zh) 2020-09-25
PL3233852T3 (pl) 2020-12-14
MY198354A (en) 2023-08-28
US12233052B2 (en) 2025-02-25
IL251370A0 (en) 2017-05-29
AU2020200407B2 (en) 2021-04-08
TW202028204A (zh) 2020-08-01
CO2017003070A2 (es) 2017-07-11
SG10202100799PA (en) 2021-03-30
US10966963B2 (en) 2021-04-06
JP2017538725A (ja) 2017-12-28
IL251370B (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
DOP2015000058A (es) Derivados tricíclicos de quinolinas y de quinoxalinas
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
EP3334719A4 (en) SUBSTITUTED BENZIMIDAZOLE, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
CL2017002605A1 (es) Derivados de indol
MX2021000029A (es) Profarmacos y moduladores de receptores nmda, sales y usos de estos.
AR122456A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos